EkoSonic Endovascular System
DeviceThe EkoSonic Endovascular System will be used to deliver < 20 mg of rt-PA ( Actilyse) directly into the occlusive pulmonary thrombus.
NCT Number: NCT01166997
The ULTIMA study is intended to prove that in patients with pulmonary embolism and a right ventricular end diastolic diameter to left ventricular end diastolic diameter ratio ≥1 (RV/LV ratio) will benefit from treatment with ultrasound accelerated thrombolysis (rt-PA) as compared to unfractionated heparin anticoagulation. Specifically, at 24 hours the RV/LV ratio will be significantly reduced in the treatment arm compared to the control arm.
Looking for future studies?
Notify Me18 year–80 year
All sexes
Interventional
Phase 3
Klinikum Lippe-Detmold, Detmold, Germany
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The EkoSonic Endovascular System will be used to deliver < 20 mg of rt-PA ( Actilyse) directly into the occlusive pulmonary thrombus.
Intravenous unfractionated heparin used for anticoagulation treatment
Time frame: 24 hours
Change in the end-diastolic RV/LV ratio from baseline to 24 hours by echocardiography.
Time frame: 30 days
Bleeding will be classified as major if it is associated with a fall in the hemoglobin level of at least 2.0 g/dl, transfusion of ≥ 2 units of red blood cells, or involvement of a critical site (e.g., intracranial, intraspinal). To aid in evaluating the relationship of bleeding events to rt-PA administration, they will also be categorized by whether they occurred within 3 days after the initiation of thrombolytic therapy.
Boston Scientific Corporation
Industry
Randomized, Controlled Study Comparing EKOS EkoSonic Ultrasound Accelerated Thrombolysis to Anticoagulation in the Treatment of Sub-massive Pulmonary Embolism
Acronym: ULTIMA
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02692586
Acute Pulmonary Embolism, Cardiovascular Diseases
Auburn, Alabama, United States
View Trial DetailsNCT01899339
Submassive Pulmonary Embolism
Grand Rapids, Michigan, United States
View Trial DetailsNCT03389971
Submassive Pulmonary Embolism
Atlanta, Georgia, United States
View Trial DetailsNCT00191724
Submassive Pulmonary Embolism
Mannheim, Germany
View Trial Details